Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Williams

Podiatrist, Foot & Ankle Surgery Davison, MI Doctor of Podiatric Medicine

NPI 1669575478 CMS profile 74861

605 S State St, Davison, MI 48423

Open in the dashboard

General payments

$4,990

88 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Williams of Davison, MI is reported in the CMS Open Payments database as having received $4,990 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $878 13
2024 General $1,106 16
2023 General $1,020 14
2022 General $364 8
2021 General $994 21
2020 General $265 8
2019 General $363 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Williams
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Mark Williams were reported at $878. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Mark Williams Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $363 $389 $118–$1,406 $163
2020 $265 $191 $62–$691 $114
2021 $994 $329 $104–$1,341 $132
2022 $364 $419 $125–$1,611 $149
2023 $1,020 $377 $128–$1,164 $160
2024 $1,106 $394 $134–$1,168 $164
2025 $878 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,961 30 payments
  2. Smith+Nephew, Inc. $747 10 payments
  3. Rikco International, LLC $718 15 payments
  4. Zimmer Biomet Holdings, Inc. $194 2 payments
  5. Treace Medical Concepts, Inc. $186 2 payments
  6. Bioventus LLC $184 2 payments
  7. Paragon 28, Inc. $168 4 payments
  8. Cardiovascular Systems Inc. $161 3 payments
  9. Organogenesis Inc. $155 7 payments
  10. MIMEDX Group, Inc. $148 2 payments
  11. Other $369 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,242 71 payments
  2. Education $748 17 payments
Products named General payments · program years 2019–2025
  1. DR. COMFORT Diabetic Shoes and Inserts $718 15 payments
  2. ORTHOLOC 2 LAPIFUSE $422 4 payments
  3. GRAFIX PL $321 4 payments
  4. ALLOMATRIX $288 3 payments
  5. ORTHOLOC 3DI $222 2 payments
  6. PROPHECY $193 5 payments
  7. EXOGEN ULTRASOUND BONE HEALING SYSTEM $184 2 payments
  8. AUGMENT INJECTABLE $174 2 payments
  9. PULSE POINT $156 3 payments
  10. PROSTEP MICA $152 1 payment
  11. Other $2,992 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

229

Median for Podiatry: 160

Drug cost

$1,752

Median for Podiatry: $2,368

Branded share of claims

57.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 24 $433
Terbinafine Hcl Generic 18 $303
Cephalexin Generic 22 $229
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 78 $228
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 26 $209
Econazole Nitrate Generic 11 $203
Clindamycin Hcl Generic 12 $65
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 27 $57
Levofloxacin Generic 11 $25

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$284,640

Of which drugs: $90

Medicare patients

529

Average age 75

Services billed

2,504

279 women, 250 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 49%
Ischemic heart disease 35%
Chronic kidney disease 35%
Atrial fibrillation 26%
COPD 26%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 73 134 $90

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record